CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?

CME Group generated nearly $6.5B of fiscal-2025 revenue (+6.4%), approximately $4.0B of net income and a sector-leading 62% net margin, versus Morningstar's $2.4B revenue (+7.5%) and 15.3% margin. Morningstar screens cheaper at a 15.5x forward P/E and 2.9x sales, compared with CME at 22.5x and 15.2x, but CME's low 0.1 debt-to-equity ratio, roughly $4.2B free cash flow and dividend support the author's preference. The article remains cautious overall, citing CME's premium valuation and Morningstar's weaker historical returns, while noting neither has matched the S&P 500 over longer periods.

Analysis

The relevant distinction is not headline margin but earnings sensitivity: CME monetizes realized and implied volatility almost immediately, while MORN's subscription base should be steadier but has less operating leverage and greater exposure to asset-manager budget scrutiny. CME's premium is defensible only if rates, equity-index, energy and options volumes remain elevated simultaneously; a normalization in volatility and policy-rate uncertainty would expose a multiple supported by peak-like transaction economics. Conversely, a sustained volatility regime makes CME a cleaner hedge against portfolio stress than ICE, whose mix has relatively more mortgage, data and fixed-fee characteristics.

MORN's apparent valuation discount may reflect more than leverage: AI distribution can commoditize basic research interfaces, shifting value toward proprietary datasets, workflow integration and benchmark/IP licensing. The key verification point is whether AI partnerships produce net revenue retention, seat expansion and pricing uplift rather than merely higher technology expense. SPGI and MSCI have stronger index and embedded-workflow pricing power, so broad AI enthusiasm is more likely to favor those incumbents unless MORN demonstrates measurable conversion in its Wealth and PitchBook-related products.

The prediction-market initiative is strategically more important to CME's long-run multiple than near-term earnings. If regulatory structure permits institutional-grade event contracts and liquidity concentrates on CME clearing, it expands addressable volume and raises the strategic cost for CBOE and ICE of remaining outside the category; if retail liquidity instead accrues to consumer platforms, CME may bear development and regulatory costs without material economics. Near term, this article itself is not a catalyst; wait for monthly volume, open-interest and take-rate disclosure rather than extrapolating from the announcement.

Key Decisions for Investors

• Maintain CME as a defensive quality holding, but do not add solely on the margin narrative. Add only on a 8-10% pullback or after evidence of two consecutive months of broad-based ADV growth; target 10-15% upside over 6-12 months, with thesis impaired by falling rates/volatility driving transaction revenue below management's implied operating-cost absorption level.
• Implement a 3-6 month relative-value pair: long CME / short ICE in equal beta-adjusted dollars when the MOVE/VIX complex is rising. CME should have greater upside torque to macro uncertainty; exit if volatility recedes materially for 4-6 weeks or ICE's data/services growth reaccelerates enough to offset the transaction-volume differential.
• Keep MORN on watch rather than initiate. A long becomes actionable if quarterly organic revenue growth accelerates above the current run rate while leverage declines and management discloses AI-linked retention or upsell metrics; absent that evidence, prefer SPGI or MSCI for data/index exposure despite their richer valuations.
• Monitor CME prediction-market disclosures and FLUT regulatory commentary over the next 1-3 quarters. Treat material open-interest growth, institutional participation and favorable CFTC clarity as an upside-multiple catalyst; adverse regulatory action or weak liquidity is a reason to remove any optionality premium from CME.